Combined HRT (Estrogen + Progestogen)
treatmentFDA-approved products and separate-component regimens exist. Compounded hormones are not FDA-approved.
Cost information
Quote required
Combined HRT is often described as estrogen plus progesterone, but that label can hide important differences. Some products use progesterone, others a different progestogen. Some combine hormones in one product; others use separate prescriptions. This guide helps you read the plan being offered and ask the right questions instead of treating every “HRT subscription” as the same treatment.
Dosage Format
Product and schedule vary. A prescriber decides whether continuous or cyclic treatment is appropriate.
Type
Treatment
Who to discuss it with
A clinician assessing menopausal symptoms, uterus status, medical history, and treatment goals
Key distinction
“Combined” refers to a regimen using estrogen and a progestogen; it does not necessarily mean one pill.
Updated · By Treatment Comparison Editorial Team · Sources and scope
Sources: ACOG: Hormone therapy for menopause · NHS: Continuous combined HRT · FDA: Menopause and hormone treatment · FDA: February 2026 hormone-therapy labeling changes
Read an HRT plan in three separate layers
| Layer | What to record | Why it matters for comparison |
|---|---|---|
| Ingredients | The estrogen and the specific progestogen, if included. | “Progesterone” and “progestogen” are not interchangeable names for every product. |
| Route | Tablet, patch, gel, or another prescribed formulation. | A combined pill and a patch-plus-pill plan have different routines. |
| Schedule | Which product is used on which days. | Continuous and cyclic regimens should not be assumed identical. |
Sources: ACOG: Hormone therapy for menopause
Continuous and cyclic treatment are different schedules
Continuous combined HRT uses both hormones daily. Cyclic or sequential treatment uses a progestogen during part of the cycle. NHS guidance generally places continuous combined HRT after menopause and sequential treatment earlier in the transition. Menstrual history therefore matters; let the prescriber select the schedule.
Sources: NHS: Continuous combined HRT
What changed in FDA labeling in 2026
In February 2026, FDA announced boxed-warning changes for six menopausal hormone products. Cardiovascular disease, breast cancer, and probable dementia statements were removed from those boxed warnings. The change concerned particular products and warning placement; it does not erase the need to discuss benefits and risks or make compounded products FDA-approved.
A useful question for a provider is: “Which current label applies to my prescription, and which parts of my history change the decision?” This is more precise than accepting a blanket claim that hormone therapy is either dangerous for everyone or safe for everyone.
Sources: FDA: February 2026 hormone-therapy labeling changes
A fair way to compare the cost of two care plans
First write out each proposed prescription. Then separate the cost of care from the cost of medication. A membership with pharmacy charges billed elsewhere cannot be compared directly with a package that includes both. For two-product regimens, ask whether the quote covers both medicines.
If a service quotes a monthly equivalent but bills quarterly, record both the equivalent and the actual payment due. Also ask how much a change of formulation, follow-up appointment, or refill costs. We removed the previous broad price range because it was not a verified quote for a defined regimen.
- What exact products are included, and are they FDA-approved?
- Are medication and clinical follow-up billed together or separately?
- Can the prescription be filled through my chosen pharmacy?
- How are treatment changes, bleeding concerns, and renewal questions handled?
- What is the cancellation deadline, and what is refundable?
“Bioidentical” is not a shortcut for assessing quality
FDA states that it lacks evidence that compounded “bioidentical” hormones are safer or more effective than approved hormone therapy. A word in the marketing copy is not enough to classify the prescription. Check the actual drug, manufacturer or compounding pharmacy, and reason for the chosen formulation.
Sources: FDA: Menopause and hormone treatment
How Combined HRT (Estrogen + Progestogen) Works
Systemic estrogen can relieve hot flashes and night sweats. For someone with a uterus, a progestogen is generally added to reduce the risk to the uterine lining from systemic estrogen alone. Local vaginal therapy is a different treatment decision; do not apply a systemic-HRT rule to every vaginal product without checking with the prescriber.
Side Effects
Common
- • Breast tenderness
- • Headache
- • Vaginal bleeding or spotting, especially when starting or changing treatment
Serious risks and warning signs
- • Blood clots, stroke, and other risks require an individualized discussion
- • Breast-cancer considerations depend on the regimen and personal history
- • Unexplained or persistent vaginal bleeding needs assessment
Eligibility to Discuss With a Clinician
Suitability depends on symptoms, medical history, and the exact prescription. Tell the clinician about unexplained bleeding and any history of hormone-sensitive cancer, clots, stroke, or liver disease. This page cannot determine eligibility or replace an assessment.
Related Medications
Provider Reviews
Explore providers in the menopause / hrt category. This does not mean every provider offers Combined HRT (Estrogen + Progestogen); check the exact product with the provider.
Related Articles
Frequently Asked Questions
Sources and editorial notes
This is a comparison of regimen features and questions to discuss, not a prescription or a clinical review. Sources include a professional medical society, NHS patient information, and FDA guidance. UK product names are not used as evidence of U.S. availability. No current provider-specific price has been independently verified.
Content updated . Source checking is editorial work; it is not a clinical review.
- ACOG: Hormone therapy for menopauseMedical or regulatory reference · Accessed 2026-09-11
- NHS: Continuous combined HRTMedical or regulatory reference · Accessed 2026-09-11
- FDA: Menopause and hormone treatmentMedical or regulatory reference · Accessed 2026-09-11
- FDA: February 2026 hormone-therapy labeling changesMedical or regulatory reference · Accessed 2026-09-11